Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for CYYNF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: CYYNF is a Buy candidate.
CYYNF stock price ended at $0.15 on 星期一, after rising 25.00%
On the latest trading day Nov 17, 2025, the stock price of CYYNF rose by 25.00%, climbing from $0.15 to $0.15. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.15 and a high of $0.15. Alongside this price increase, trading volume also rose by 3.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 2.0K shares were traded, amounting to a market value of approximately $35.6M.
投资组合